Otonomy, Inc. announced that Chau Q. Khuong resignation of board of directors and from his positions on the audit and compensation committees in order to devote additional attention to his responsibilities as a private equity partner at OrbiMed Advisors. The decision of Mr. Khuong to resign is not the result of any disagreement with the company on any matter relating to its operations, policies or practices. The board appointed Iain McGill to the board of directors and to the audit committee. Mr. McGill has served as senior vice president, Jazz Pharmaceuticals Europe and Rest of World for Jazz Pharmaceuticals PLC since March 2015. In this role, he has responsibility for all ex-U.S. operations and leads a multidisciplinary team covering commercial, development, medical, legal, compliance, business development and finance. From March 2014 to March 2015, Mr. McGill served as head of EUSA Pharma and senior vice president, Jazz Pharmaceuticals, and as chief commercial officer, EUSA Pharma, a specialty pharmaceutical company, from June 2012 to March 2014, when he joined Jazz Pharmaceuticals in connection with its acquisition of EUSA Pharma. From October 2011 to June 2012, Mr. McGill served as chief commercial officer at EUSA Pharma (Europe) Ltd. From August 2010 to September 2011, he served as president Europe, international & global marketing of EUSA Pharma (Europe) Ltd, and from January 2010 to July 2010, as president of Europe. From 2006 to 2009, Mr. McGill served as vice president and global business manager at Wyeth, a pharmaceutical company acquired by Pfizer Inc. Previously, Mr. McGill held commercial positions of increasing responsibility over thirteen years with Novartis, Roche and Syntex and the board announced Retirement of Chief Scientific Officer: Otonomy’s chief scientific officer, Carl LeBel, Ph.D., has informed the company of his plan to retire from full-time employment. Dr. LeBel will continue in a full-time capacity until his replacement has been hired plus an additional transition period. After that, Dr. LeBel has committed to provide consulting support for an extended period. The company has initiated a search for a suitable replacement.